DNAM-1/CD226 Antibody (102511) [Unconjugated]

Recombinant Human DNAM-1/CD226 Fc Chimera (Catalog # 666-DN), immobilized onto a microplate, supports the adhesion of the COLO 205 human colorectal adenocarcinoma cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human DNAM-1/CD226 Fc Chimera (20 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human DNAM-1/CD226 Monoclonal Antibody (Catalog # MAB666). The ND50 is typically 0.1-0.6 µg/mL.

Human peripheral blood mononuclear cells (PBMCs) gated on CD3- cells were stained with Mouse Anti-Human NCAM‑1/CD56 APC‑conjugated Monoclonal Antibody (Catalog # FAB2408A) and either (A) Mouse Anti-Human DNAM-1/CD226 Monoclonal Antibody (Catalog # MAB666) or (B) Mouse IgG1 Isotype Control (Catalog # MAB002) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B).

• Reactivity: Hu
• Applications: WB, Flow, B/N, CyTOF-ready
• Clone: 102511
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

DNAM-1/CD226 Antibody (102511) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human DNAM-1/CD226
  Glu19-Asn247 (predicted)
  Accession # Q15762
• Specificity: Detects human DNAM-1/CD226 in direct ELISAs and Western blots.
• Details of Functionality: ActivityAssaywCitation not found None None None
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CD226
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Western Blot 1 ug/mL
  • Flow Cytometry 0.25 ug/10^6 cells
  • CyTOF-ready
  • Neutralization 0.1-0.6 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for DNAM-1/CD226 Antibody (102511) [Unconjugated]

• CD226 antigenplatelet and T cell activation antigen 1
• CD226 molecule
• CD226
• DNAM1
• DNAM-1
• DNAM1adhesion glycoprotein
• DNAM-1DNAX accessory molecule-1
• DNAX accessory molecule 1
• PTA1
• T lineage-specific activation antigen 1 antigen
• TLiSA1

Background

DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily (1). Mature human DNAM-1 contains a 236 amino acid (aa) extracellular domain (ECD) with two Ig-like C2-set domains and a 61 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, human DNAM-1 shares 50% and 52% aa sequence identity with mouse and rat DNAM-1, respectively. DNAM-1 is expressed on multiple lymphoid and myeloid cell types and interacts with CD155/PVR and Nectin-2/CD112 (3, 4). Ligation of DNAM-1 promotes the activation of NK cells, CD8⁺ T cells, and mast cells (2‑6), dendritic cell maturation, megakaryocyte and activated platelet adhesion to vascular endothelial cells, and monocyte extravasation; it inhibits the formation of osteoclasts (7‑10). Platelet-endothelium interactions mediated by DNAM-1 enable the metastasis of tumor cells to the lung (11). In activated, but not in resting NK, T, and mast cells, the cis association of DNAM-1 with CD18 contributes to the tyrosine and serine phosphorylation of DNAM-1 during activation (6, 9, 12‑14).

1. Fuchs, A. and M. Colonna (2006) Semin. Cancer Biol. 16:359.
2. Shibuya, A. et al. (1996) Immunity 4:573.
3. Bottino, C. et al. (2003) J. Exp. Med. 198:557.
4. Tahara-Hanaoka, S. et al. (2004) Int. Immunol. 16:533.
5. Dardalhon, V. et al. (2005) J. Immunol. 175:1558.
6. Bachelet, I. et al. (2006) J. Biol. Chem. 281:27190.
7. Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
8. Kakehi, S. et al. (2007) Mol. Cell. Biochem. 301:209.
9. Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
10. Tahara-Hanaoka, S. et al. (2006) Blood 107:1491.
11. Morimoto, K. et al. (2007) Oncogene July 16 epub.
12. Shibuya, K. et al. (1999) Immunity 11:615.
13. Shibuya, K. et al. (2003) J. Exp. Med. 198:1829.
14. Shibuya, A. et al. (1998) J. Immunol. 166:1671.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for DNAM-1/CD226 Antibody (MAB666)(6)

Publications using MAB666

• M Najar, M Fayyad-Kaz, N Meuleman, D Bron, H Fayyad-Kaz, L Lagneaux Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation J Cell Commun Signal, 2018;0(0):. 2018 [PMID: 29350342] (Neutralization, Human)
• S López-Cobo, N Pieper, C Campos-Sil, EM García-Cue, HT Reyburn, A Paschen, M Valés-Góme Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors Oncoimmunology, 2018;7(2):e1392426. 2018 [PMID: 29308322] (Bioassay, Human)
• JL Espinoza, LQ Trung, PT Inaoka, K Yamada, DT An, S Mizuno, S Nakao, A Takami The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans Oxid Med Cell Longev, 2017;2017(0):6781872. 2017 [PMID: 28546852] (Flow Cytometry, Human)
• Davis Z, Sowrirajan B, Cogswell A, Ward J, Planelles V, Barker E CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells. AIDS Res Hum Retroviruses, 0;33(2):93-100. 0 [PMID: 27296670] (Neutralization, Human)
• Huijskens M, Walczak M, Sarkar S, Atrafi F, Senden-Gijsbers B, Tilanus M, Bos G, Wieten L, Germeraad W Ascorbic acid promotes proliferation of natural killer cell populations in culture systems applicable for natural killer cell therapy. Cytotherapy, 0;17(5):613-20. 0 [PMID: 25747742] (Flow Cytometry, Human)
• Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, Gregori S Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur. J. Immunol., 2011;41(6):1652-62. 2011 [PMID: 21469116] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: CD226
• Uniprot:
  • Q15762()